Technical Report Hematology Otolaryngology
Does an antibiotic stewardship programme reduce length of stay in children with asthma? A quality-improvement audit

Does an antibiotic stewardship programme reduce length of stay in children with asthma? A quality-improvement audit

Authors

Omar Farouk

Omar Farouk

Royal Melbourne Hospital, New Caledonia

Zainab Schmidt

Zainab Schmidt

Hamad Medical Corporation, Eritrea

Leo Volkov

Leo Volkov

Charité Berlin, Saint Helena

Corresponding
Lucas Yilmaz

Lucas Yilmaz

Cleveland Clinic Abu Dhabi, Svalbard and Jan Mayen Islands

Felix Patel

Felix Patel

Aga Khan University Hospital, Bulgaria

Layla Silva

Layla Silva

American University of Beirut Medical Center, Kuwait

Published

April 17, 2025

Paper ID

PAP-000275

Status

Published

DOI

10.65712/tmj.test000533

Does an antibiotic stewardship programme reduce length of stay in children with asthma? A quality-improvement audit

Advance Services

Create Content

Video • Presentation • Poster

From $97.00 per format

Abstract

Background: length of stay remains a leading cause of avoidable harm among children with asthma. Methods: The primary outcome was length of stay, assessed blind to allocation. Results: Effects were consistent across prespecified subgroups. Serious adverse events were rare and similar between groups. Conclusion: Strengths include the sample size and blinded outcome assessment.

Introduction

Earlier studies of an antibiotic stewardship programme were small or single-centre. length of stay remains a leading cause of avoidable harm among children with asthma. Guidelines make only a weak recommendation on an antibiotic stewardship programme.

The cost of length of stay to health systems is substantial. Guidelines make only a weak recommendation on an antibiotic stewardship programme. length of stay remains a leading cause of avoidable harm among children with asthma.

Earlier studies of an antibiotic stewardship programme were small or single-centre. length of stay remains a leading cause of avoidable harm among children with asthma.

Practice around an antibiotic stewardship programme varies widely between centres.

Discussion

Residual confounding cannot be excluded. Strengths include the sample size and blinded outcome assessment. These findings suggest that an antibiotic stewardship programme is associated with better length of stay in children with asthma.

Strengths include the sample size and blinded outcome assessment. Residual confounding cannot be excluded.

Strengths include the sample size and blinded outcome assessment. Implementation will depend on staffing, cost and local protocols. Residual confounding cannot be excluded. These findings suggest that an antibiotic stewardship programme is associated with better length of stay in children with asthma.

Strengths include the sample size and blinded outcome assessment. Residual confounding cannot be excluded.

Conclusions

An antibiotic stewardship programme is a reasonable option for children with asthma to improve length of stay.

References

1. Patel H, Mensah X, et al. An antibiotic stewardship programme and health-related quality of life. Crit Care Med. 2019;35(4):571-1039.

2. Rahman O, Volkov O, et al. Continuous glucose monitoring and surgical site infection. Diabetes Care. 2011;164(8):517-989.

3. Silva J, Rahman R, et al. Continuous glucose monitoring and 30-day readmission. N Engl J Med. 2014;222(1):647-1039.

4. Kowalski Z, Costa F, et al. An enhanced recovery pathway and post-operative delirium. Crit Care Med. 2024;99(2):551-1270.

5. Andersen G, Silva U, et al. Frailty screening and medication adherence. Pediatrics. 2012;326(8):284-1310.

6. Mueller K, Tanaka R, et al. Continuous glucose monitoring and emergency department revisits. BMJ. 2017;80(9):192-904.

7. Schmidt H, Ibrahim T, et al. Continuous glucose monitoring and glycaemic control. N Engl J Med. 2012;264(1):636-1539.

Appendices

The statistical analysis plan is in the online supplement.

Materials and Methods

Missing data were handled with multiple imputation. The primary outcome was length of stay, assessed blind to allocation. Eligible participants were children with asthma.

The primary outcome was length of stay, assessed blind to allocation. Eligible participants were children with asthma.

The primary outcome was length of stay, assessed blind to allocation. We conducted a quality-improvement audit across 12 centres between 2017 and 2021. Missing data were handled with multiple imputation. We conducted a quality-improvement audit across 14 centres between 2016 and 2025.

We conducted a quality-improvement audit across 10 centres between 2017 and 2025. The primary outcome was length of stay, assessed blind to allocation. Eligible participants were children with asthma.

Results

1719 participants were included (median age 36 years). Effects were consistent across prespecified subgroups. Serious adverse events were rare and similar between groups.

The adjusted odds ratio was 0.76 (95% CI 0.50 to 0.98). The adjusted odds ratio was 0.45 (95% CI 0.39 to 0.96). Serious adverse events were rare and similar between groups. length of stay occurred in 17% of the intervention group versus 28% of controls.

Effects were consistent across prespecified subgroups. The adjusted odds ratio was 0.84 (95% CI 0.38 to 0.88).

GroupnEventsRate %OR95% CI
Male321739.10.490.47–1.38
Centre A809561.00.740.22–1.19
Centre B7441009.50.420.60–1.9
Male670909.80.750.49–1.30
Age ≥ 6535119.30.830.57–1.40
Female2956735.70.850.40–1.15
TABLE 1: Primary outcome by group
Values are n (%) unless stated otherwise.
Figure 1
FIGURE 1: Change in length of stay
Shown for children with asthma; error bars are 95% confidence intervals.

Effects were consistent across prespecified subgroups. The adjusted odds ratio was 0.52 (95% CI 0.22 to 0.76).